$SGRY

Surgery Partners, Inc. (SGRY): Completion of Acquisition or Disposition of Assets

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. SURGERY PARTNERS, INC. Unaudited Pro Forma Condensed Consolidated Financial Statements On September 14, 2026, Surgery Partners, Inc. (the "Company"), through certain of its subsi diaries, entered into two Securities Purchase Agreements (the "Agreements") to sell it's ownership in

Original reporting
Published Sep 17, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$SGRY
Neutral
high confidence
Mentioned
$SGRY
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SGRYNeutralMed
01

Why it matters

The deal reshapes the company's balance sheet, increasing cash while decreasing assets and revenue streams, prompting analysts to reassess earnings forecasts.

02

Market read

Primary corporate event with material financial impact; relevant for investors holding or considering SGRY.

03

What to watch

Potential tax implications and integration costs for the buyer may affect the net benefit to shareholders.

Relevance 7/10Novelty 9/10Timing: filed Sep 17 2026 after market close

Background

Surgery Partners disclosed the disposition of two hospital assets via two Securities Purchase Agreements, detailing pro forma financial adjustments.

Company-level read

Ticker impact

$SGRYNeutralHigh confidence
Context

SEC Form 8‑K reports Surgery Partners' completion of the sale of its interests in Mountain View Hospital and Ida Ho Falls Community Hospital for approximately $796.6 million.

Expected impact

Modest upside from cash receipt offset by loss of future earnings; expect limited net price movement.

Evidence & confidence

Cash proceeds are sizable, yet the disposed assets contributed significant revenue; market will price the net effect.

Market effects

Reduces Surgery Partners' exposure to the hospital services segment, potentially benefiting peers with unchanged exposure.

No immediate regional effect beyond the U.S. healthcare services market.

Limited to U.S. healthcare investors; not a broad market driver.

Counterpoint

The cash boost could be undervalued if the sold assets were underperforming, offering a buying opportunity.

Key entities

  • Surgery Partners, Inc.

    U.S. healthcare services provider filing the 8‑K.

  • Intermountain Health

    Acquirer of the hospital interests.

Related articles

$SGRYMedAI 8/10

Surgery Partners (SGRY) Q2 2026 Earnings Call Transcript

Surgery Partners (SGRY) reported Q2 2026 net revenue of about $849 million, up 2.7% year over year, and adjusted EBITDA of about $125 million, with a 14.7% margin. Same-facility net revenue rose 5%. For the first half, net revenue was about $1.66 billion (+3.6%) and adjusted EBITDA about $228 million. The company reaffirmed full-year guidance and said it will update forward guidance after a pending Idaho Falls transaction closes.

$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

$SGRYMed

Surgery Partners Q2 Earnings Call Highlights

Surgery Partners (NASDAQ:SGRY) reported Q2 same-facility revenue up 4.9% for the first half, driven by a 0.8% case increase and 4% net revenue per case. Management said commercial payer mix fell to about 49% of Q2 net revenue, with government payments rising. The company signed agreements to sell Idaho Falls assets for about $795M gross consideration and reaffirmed 2026 guidance excluding the deal.

$SGRYMed

Surgery Partners shares edge lower despite Q2 revenue beat

Surgery Partners (NASDAQ:SGRY) shares fell 0.71% pre-market after Q2 results were mixed. Revenue rose to $848.9M, above the $830.05M forecast, and same-facility revenue grew 5%. Adjusted EPS was $0.10 vs $0.06 consensus, but GAAP net loss was $0.12/share. Adjusted EBITDA fell to $125.2M. Company reaffirmed 2026 revenue $3.35B-$3.45B and adjusted EBITDA at least $530M.

$SGRYMedAI 8/10

Surgery Partners Q2 2026 slides show 5% revenue growth, Idaho exit

Surgery Partners (NASDAQ:SGRY) reported Q2 2026 revenue of $848.9M, above an $830.05M estimate, but posted an adjusted loss of $0.12 per share versus a $0.06 profit expectation. Same-facility revenue grew 5.0% on 4.8% rate growth. The company reaffirmed 2026 guidance: $3.35B to $3.45B revenue and at least $530M adjusted EBITDA, excluding the pending Idaho Falls divestiture.